EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Sees Large Increase in Short Interest

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 10,340,000 shares, a growth of 9.9% from the December 31st total of 9,410,000 shares. Based on an average daily trading volume, of 956,300 shares, the short-interest ratio is presently 10.8 days.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Greenwich Wealth Management LLC boosted its stake in shares of EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company's stock valued at $93,000 after buying an additional 900 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in EyePoint Pharmaceuticals by 68.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock worth $82,000 after acquiring an additional 4,172 shares during the last quarter. Cyndeo Wealth Partners LLC grew its holdings in EyePoint Pharmaceuticals by 35.5% during the 4th quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company's stock worth $127,000 after acquiring an additional 4,450 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of EyePoint Pharmaceuticals by 5.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company's stock valued at $1,141,000 after purchasing an additional 7,967 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of EyePoint Pharmaceuticals by 16.1% in the 4th quarter. Rhumbline Advisers now owns 89,560 shares of the company's stock valued at $667,000 after purchasing an additional 12,443 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company's stock.

Analysts Set New Price Targets

A number of analysts have issued reports on EYPT shares. Chardan Capital raised their target price on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 price objective for the company. Scotiabank began coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $18.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Finally, Robert W. Baird reduced their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. According to MarketBeat, EyePoint Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $26.63.

EyePoint Pharmaceuticals Stock Up 2.4 %

NASDAQ EYPT traded up $0.18 on Wednesday, reaching $7.80. The stock had a trading volume of 3,325,570 shares, compared to its average volume of 830,052. EyePoint Pharmaceuticals has a 12-month low of $6.55 and a 12-month high of $30.99. The stock has a fifty day moving average price of $7.97 and a two-hundred day moving average price of $8.84. The firm has a market capitalization of $532.36 million, a price-to-earnings ratio of -3.90 and a beta of 1.51.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.06). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $10.52 million during the quarter, compared to analyst estimates of $12.35 million. Sell-side analysts forecast that EyePoint Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.